Key facts
- It has raised $85.0M; the latest was PE Growth/Expansion ($85.0M) in Apr 2026.
- Notable investors include OrbiMed.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for SpectronRx
- ·The full record, as it builds
Funding rounds
No funding rounds for SpectronRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SpectronRx
Operator of a contract development and manufacturing platform intended to support the production and supply of radiopharmaceuticals and isotopes for nuclear medicine applications. The company offers contract manufacturing services, isotope production capabilities, cyclotron operations, and custom drug synthesis and automation, enabling pharmaceutical and biotechnology companies to develop, manufacture, and supply therapeutic and diagnostic radiopharmaceutical products for clinical and research use.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2004
- Employees
- 285
- Website
- spectronrx.com/
- Ownership
- Privately Held (backing)
SpectronRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SpectronRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SpectronRx in its N-PORT filings yet. We sweep new filings monthly.